Cargando…
678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
BACKGROUND: In June 2021, IDSA updated its guideline to have fidaxomicin (FDX) as the preferred treatment over vancomycin (VAN) for patients with initial and recurrent CDI. The objective of this study was to examine changes in treatment pattern for CDI and variation in implementation of the guidelin...
Autores principales: | Dubberke, Erik R, Li, Qinghua, Obi, Engels N, Turzhitsky, Vladimir, Siddiqui, Fakhar, Nathanson, Brian H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678449/ http://dx.doi.org/10.1093/ofid/ofad500.740 |
Ejemplares similares
-
15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S
por: Dubberke, Erik R, et al.
Publicado: (2021) -
Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022) -
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021) -
Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022) -
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)